Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Friday 23 October 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Oncology

12 Questions with Julia Jakl

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

MDM concept of patient data

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Sales & Marketing

The dangers of social media for pharma

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

A sponsored video interview with Axria's Jeff Kaminski

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Patients

pharmaphorum podcast Episode 281 - Cecilia Caetano, Bayer

Sponsored

Menopause is an urgent global health issue: Bayer’s Cecilia ...

Articles

How and why navigating unstructured data in biopharma industry is gaining attention

How and why navigating unstructured data in biopharma indust...

As our R&D innovation focus month continues, Will Zerhouni discusses the whys and hows of the biopharma industry’s need to navigate data. The biopharma industry and academic research centers combine to produce hundreds of thousands of data points annually with...

Articles

Tunnah’s musings: the biggest barrier to digital healthcare is…

Tunnah’s musings: the biggest barrier to digital healthcare ...

This month, Paul Tunnah cuts through the endless debate about the latest greatest new piece of healthcare technology, website or app and focusses on the real challenge in this space. Modern cars are full of amazing technology. I can still remember learning to drive many years ago, when about the most complex piece of technology you would find on a car was …

Articles

How and why navigating unstructured data in biopharma industry is gaining attention

How and why navigating unstructured data in biopharma indust...

As our R&D innovation focus month continues, Will Zerhouni discusses the whys and hows of the biopharma industry’s need to navigate data. The biopharma industry and academic research centers combine to produce hundreds of thousands of data points annually with...

Load more results

Sales & Marketing

Sales & Marketing

The dangers of social media for pharma

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Sales & Marketing

Female pharmacist with male patient in pharmacy

Your DTP programme has five vendors and no spine

Over the past few years, many pharma brands set out to build a direct-to-patient (DTP) channel. The website went live. A telehealth partner was selected. Pharmacy logistics were set up.

Digital

Digital

A sponsored video interview with Axria's Jeff Kaminski

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital

Data analytics and batch release

Better analytics leads to fewer regulator questions

Stronger data analytics is cutting the number of questions regulators ask about intensified processes.

Market Access

Market Access

MDM concept of patient data

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Market Access

Two pills in the middle of multiple £1 coins

UK’s next pricing and access scheme to last for 7 years

Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.

Editor's Picks

CHMP backs Lilly's oral GLP-1 Foundayo for EU approval

RevMed nears EU okay for pancreatic cancer drug Rasonque

Roche adds another obesity drug with $1.16bn Rona deal

MHRA lays out its thinking on AI and medicines regulation

GSK planning 1,200 job cuts in Belgium, says paper

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

12 Questions with Julia Jakl

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Oncology

Dr Michael Bauer and Jonah Comstock

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.

Oncology

Cancer cell and T-cells

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

Patients

Patients

pharmaphorum podcast Episode 281 - Cecilia Caetano, Bayer

Sponsored

Menopause is an urgent global health issue: Bayer’s Cecilia ...

Patients

female HCP confers with female patient

From bedside to breakthroughs: Reimagining the human experie...

Patients should be involved in the programme design process from the beginning, as co-creators with full influence over the outcome.

Patients

Hispanic heritage

Breaking Bipolar I disorder stigma in the Hispanic community

For many Hispanic patients and families, that is where the gap between need and treatment can begin.

R&D

R&D

Wooden pawns on top of wooden block named BOARD

Changing Faces: Board of Director and Advisory Board hires, ...

September’s boardroom moves brought seasoned pharma executives, investors, and scientific leaders into new governance and advisory roles across the life sciences sector.

R&D

Digital box and pills, supply chain concept for pharma

From reactive to predictive: How data is redefining pharma l...

Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight.

R&D

Depressed woman looks out rain spattered window in city

Removing barriers in treatment-resistant depression

pharmaphorum speaks with Hans Eriksson, psychiatrist and CMO of FundaMental Pharma, about why treatment resistance remains such a challenge.

Editor's Picks

CHMP backs Lilly's oral GLP-1 Foundayo for EU approval

RevMed nears EU okay for pancreatic cancer drug Rasonque

Roche adds another obesity drug with $1.16bn Rona deal

MHRA lays out its thinking on AI and medicines regulation

GSK planning 1,200 job cuts in Belgium, says paper

News

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company